ASH 2022

CLL cells

ASH 2022: New Findings in CLL

Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.

Next post in ASH 2022